09 - 10 June 2022 | Berlin, Germany
+ Digital Day: 13 June 2022 | Online
Discovery Europe
09 - 10 June 2022 | Berlin, Germany
+ Digital Day: 13 June 2022 | Online

Join and network with over 500 industry leaders at the renowned Drug Discovery Summit in Berlin, where we will address the latest advancements in target identification, validation and HIT optimisation.

Exploring the latest advancements in phenotypic and target-based discovery, chemical biology as well as drug design at our two-day summit.

The event will bring together leading experts in the fields of Organoid Discovery, Phenotypic Screening, Targeted Protein Degradation, AI Computational Drug Design and Lead Optimisation.

Programmes

Benefits to attending include…

Join and network with over 500 industry leaders at Discovery Europe: In-Person, where we will address the latest advancements in target identification, validation and HIT optimisation.

The 2-day programme addresses drug discovery in new modalities such as protein degradation, and case studies on the integration of screening approaches in phenotypic and genomics-based discovery, Organ-on-a-chip and 3D modelling.

Learn about key focus areas in drug design including AI in drug design: in chemical synthesis, target ID capabilities & lead identification/optimisation.

Join our 2-day innovation showcase situated alongside the main programme, which aims to inspire growth and create collaboration opportunities for all who attend.

This Year's Agenda at a Glance

Day One
  • Identification And Validation Of Novel Targets For Next Generation Therapeutics.
  • Phenotypic Based Discovery And Screening.
  • New Modalities And Challenging Targets:
    Targeted Protein Degradation And PROTAC.
  • Computational Drug Design: AI In Chemical Synthesis, Target ID Capabilities, Lead Identification, Lead Optimisation, Measuring PK/PD & Prediction.
Day Two
  • Animal And Disease Modelling, Organoid And Organ On The Chip Based Discovery.
  • Drug Design And Medicinal Chemistry: Innovations In Fragment & Structured Based Drug Discovery.
  • Integration Of Technologies In The Optimization Of HITs – DEL, Covalent Inhibitors And Protein Degradation.
  • Target Identification and Validation
  • Organ Modelling
  • Molecular Glue Degraders – Development and Identification
  • E3 Ubiquitin Ligases and Targeted Protein Degradation
  • Integration of AI for HIT Development
  • Digitising Drug Discovery Labs
Digital Day

Presentations & interactive sessions on all above topics

Key Speakers

Below were some of the key speakers from our Discovery UK: In-Person 2021 event

Ian Storer

Ian Storer

Vice President of Chemistry and Hit Discovery
AstraZeneca
Malcolm Weir

Malcolm Weir

Chief Executive Officer
Sosei Heptares
Thorsten Thormann

Thorsten Thormann

Vice President, Research
Leo Pharma
Janet Brownlees

Janet Brownlees

Director, Neuroscience Biology, Discovery Research MRL UK
MSD
Sarah Stuart

Sarah Stuart

HTC Team Leader, Biopharm Discovery
GSK
Bryn Williams-Jones

Bryn Williams-Jones

Vice President Drug Discovery
BenevolentAI

Event Features​

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of on-site experiences.

Poster Display

Enhance your attendance with an A0 Poster, based in our main networking hall

Networking Drinks

Relax after a busy first day at the event with access to the vibrant drinks reception

Supported Digitally

Can't attend in-person? Our fully featured online platform runs alongside the event with a dedicated Digital Day to round off the conference after the two days on-site

Sponsorship

A range of customisable opportunities for lead generation, brand building and global business deals. Whether you’re looking to build business, product launch or increase visibility, we provide a variety of highly effective options to suit budget and requirement.

Copyright Oxford Global Marketing Limited. All rights reserved.